Oticara Announces Positive Phase 2 Results Demonstrating Durable Symptom Improvement with Novel Steroid Nasal Cream for Hard-to-Treat Post-Surgical Chronic Rhinosinusitis
Oticara, a clinical-stage pharmaceutical company developing therapies for chronic rhinosinusitis (CRS), today announced positive results from its Phase 2 OT-007B clinical trial evaluating the company’s proprietary nasal-mucosa-optimized steroid cream in patients with persistent CRS symptoms following endoscopic sinus surgery (ESS). Data were presented in a late-breaking oral podium presentation at the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting & OTO EXPO℠ in Indianapolis, Indiana.
Oticara to Present Late-Breaking Phase 2 Data on Novel Steroid Nasal Cream for Hard-to-Treat Post-surgical Chronic Rhinosinusitis Patients at AAO-HNSF 2025 Annual Meeting
Oticara, an emerging pharmaceutical company advancing physician-delivered treatments for chronic rhinosinusitis (CRS), today announced that new late-breaking clinical data from its Phase 2 OT-007B trial will be featured in an oral podium presentation at the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting & OTO EXPO℠, taking place October 11 to 14, 2025, in Indianapolis, Indiana.
